Shares of Forte Biosciences plunged after announcing that a Phase II atopic dermatitis trial assessing the company’s lead pipeline candidate failed to demonstrate statistical significance in the primary endpoint.

The U.S. Food and Drug Administration approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections in pediatric patients as young as newborns.

Data from a mid-stage clinical study of an experimental vaccine candidate developed by Affinivax and Astellas Pharma for Streptococcus pneumoniae shows ASP3772 is well tolerated and generated an antibody response against the deadly bacterial infection.

Jazz Pharmaceuticals won U.S. regulatory approval for a new leukemia drug aimed at patients who have developed hypersensitivity to E. coli-derived asparaginase, an enzyme that is a component of the chemotherapy regimen used to treat acute lymphoblastic leukemia (ALL).

Months after recovery from mild Covid-19 – when antibody levels in the blood have declined – immune cells in bone marrow remain ready to pump out new antibodies against the coronavirus, researchers reported on May 24 in Nature. And according to a new U.S. study, young children appear to be significant carriers of more contagious variants of the new coronavirus, such as the ones identified in the UK and in California.

Topline results from two of Merck’s Phase III pediatric trials show the company’s investigational 15-valent pneumococcal conjugate vaccine, V114, may be safe and effective in healthy children.

Jerusalem-based SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. Participating in the round were OrbiMed, Israel Biotech Fund, Integra Holdings and the Cystic Fibrosis Foundation.

Passage Bio Inc. and InformedDNA announced a collaboration to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with Frontotemporal Dementia (FTD).

The microscopic organisms living in our intestines may influence the severity of Covid-19 and the body’s immune response to it, and could account for lingering symptoms, researchers reported.

rBIO launched with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.